Angel News

Back to Homepage

20th May 2020

Archangels-backed MGB Biopharma has successful outcome from Phase II clinical study

MGB Biopharma, the Glasgow-based biopharmaceutical company developing a novel class of anti-infectives, has announced the successful conclusion of its Phase II clinical study into MGB-BP-3, for the treatment of Clostridium difficile Infection (CDI).

...

Register / Login now to read full story

In order to read the full story we need you to be registered with us, please click the links below to login or register.

Login / Register

Add a comment:

Name:

Email:

Comment:

Enter the characters in the image shown:



Back to Homepage